欢迎您注册蒲公英
您需要 登录 才可以下载或查看，没有帐号？立即注册
x
Warning Letter WL: 320-14-11 CERTIFIED MAIL RETURN RECEIPT REQUESTED June 16, 2014 Jeremy B. Desai, PhD President and Chief Operating Officer Apotex, Inc. 150 Signet Drive Toronto, ON, Canada M9L 1 T9 Dear Dr. Desai: During our January 27, 2014 through January 31, 2014 inspection of your pharmaceutical manufacturing facility, Apotex Pharmachem India Pvt. Ltd. located at Plot # 1A Bommasandra Ind. Area, 4th Phase, Jigani Link Road, Bangalore, India, investigators from the U.S. Food and Drug Administration (FDA) identified significant deviations from current good manufacturing practice (CGMP) for the manufacture of active pharmaceutical ingredients (APIs). These deviations cause your APIs to be adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 USC § 351(a)(2)(B), in that the methods used in, or the facilities or controls used for, their manufacture, processing, packing, or holding do not conform to, or are not operated or administered in conformity with, CGMP. We have conducted a detailed review of your firm’s response dated February 20, 2014 and note that it lacks sufficient corrective actions. We also acknowledge receipt of your firm's additional correspondence dated April 4, 2014, and May 27, 2014. 我们审核了你公司签署日期为2014年2月20日的回复，注意到你们的纠正措施不够充分。我们在此也通知你们，我们已收到你公司签署日期为2014年4月4日和5月27日的补充邮件。 Our investigators observed specific deviations during the inspection, including, but not limited to, the following: 我们的检查人员在检查过程中发现了一些偏差，包括但不仅限于以下： 1. Failure to maintain complete data derived from all laboratory tests conducted to ensure compliance with established specifications and standards. 未能维护所有化验室检测所产生的完整数据，因而无法保证与既定规格和标准的符合性。 Your firm lacked accurate raw laboratory data records for API batches shipped by your firm. The inspection revealed that batch samples were retested until acceptable results were obtained. In addition, your quality control (QC) laboratory failed to include complete data on QC testing sheets. Failing or otherwise atypical results were not included in the official laboratory control records, not reported, and not investigated. For example, 你公司缺乏你们公司发运的原料药批次的准确的原始检验数据记录。检查显示多批样品被“反复检测直至得到合格结果”。另外，你们QC化验室的检测记录中数据不完整，不合格结果或非正常结果没有包括在正式的化验室检测记录中，没有进行报告，没有进行调查。例如： · A review of the Gas Chromatograph (GC) electronic records from July 13, 2013, for (b)(4) USP batch #(b)(4)revealed an out-of-specification (OOS) result for the limit of residual solvents that was not reported. However, the QC test data sheet included passing results obtained from samples tested on July 14, 2013 and July 15, 2013. The inspection documented that your firm discarded sample preparation raw data related to the OOS results. In your response you indicate that the electronic chromatographic data and the weighing log books were available and reviewed during the inspection. However, the raw data and sample preparation information used for the calculation of the test results that were found OOS or disregarded were not in fact available for review. · 对2013年7月13日XXUSP批次气相色谱的电子记录审核中发现，一个残留溶剂OOS结果没有报告。但是，QC检测数据表中包括了该样品在2013年7月14日和15日检测得到的一个合格结果。检查记录了你们公司丢弃了与OOS结果有关的样品制备原始数据，在你们的回复中，你们说电子色谱数据和称重记录本是有的，并在检查中提供了。但是事实上，在检查过程中，你们并未能提供用于计算OOS检测结果的原始数据和样品制备信息。 · A review of the High Performance Liquid Chromatograph (HPLC) electronic records from July 3, 2013, for(b)(4) batch #(b)(4) revealed an Out-of-Trend (OOT) result. The sample preparation raw data was discarded and not reported. A QC analyst indicated that these results were discarded due to some small extra peaks identified in the chromatogram fingerprint and an unexpected high assay result. The QC test data sheet reported two new results that were obtained from samples tested on July 4, 2013 and July 5, 2013, using a different HPLC instrument. · 对2013年7月3日XX批次的HPLC检测审核发现一个OOT结果。样品制备原始数据被丢弃了，结果没有报告。一个QC化验员说，这些结果之所以被丢弃，是因为在色谱图的指纹区发现一些额外的峰，导致非预期的高含量结果。QC检测数据表报告了2个新的结果，是在2013年7月4日和5日采用另一台HPLC检测得到的。 · A review of the Karl Fischer electronic records from November 21, 2013, for (b)(4) EP batch #(b)(4) revealed an OOS result that was not reported. The passing results reported on the data sheets were generated from another sample tested an hour after the initial OOS results were obtained on the same day, November 21, 2013. · 对XX EP批号在2013年11月21日的KF电子记录审核发现一个OOS结果没有被报告。在数据表上报告了一个合格的结果，是在首次OOS结果一个小时后同一天（2013年11月21日）对另一份样品检测得到的。 According to laboratory analysts interviewed during the inspection, the common practice was to complete the analysis and to record the sample preparation data only if the results were acceptable. If the results obtained were atypical, a fresh sample was to be prepared and analyzed. The original sample testing was not recorded. 检查期间化验室的化验员说，他们一般是先完成分析操作，只有结果可以接受时，才记录样品制备数据。如果结果不正常，就会制备另一份样品重新检测，初始的检测就不记录了。 Your firm’s response states that the observations listed in the Form FDA 483 refer to work performed by analysts who did not follow the established procedures found in standard operating procedure (SOP) QC027 “Out of Specification Test Results and Investigation,” SOP QC098 “Laboratory Incidents Investigation and Resolution,” and SOP QA006 “Deviations.” In addition, your response states “[t]he examples cited in this and other observations where additional testing was conducted by the analyst resulted from a number of factors ranging from system suitability parameters not being met to equipment malfunction to available in-process test data results that were inconsistent with release results.” 你公司的回复声称在FDA483上所列的缺陷是化验员的个人行为，他们没有遵守公司所建立的标准操作程序（SOP）QC027“超标结果调查”、SOP QC098“化验室事件调查和处理”和SOP QA006“偏差”。另外，你们的回复声称“在这个缺陷和其它缺陷中所引用的例子中，化验员进行额外检测是因为很多原因，这些原因从系统适用性参数不符合到设备故障到中控检测结果与放行结果不符合”。 In addition, your response to the FDA Form-483 indicates that your firm identified similar variances from established procedures that occurred in September 2013. Your response goes on to indicate that, following this discovery, you reviewed data from the month of August 2013, and identified nine additional incidents in which extra testing was performed without maintaining appropriate laboratory records. You fail to explain why, given these troubling findings, you did not then expand your investigation to discover the full scope of such variances from established procedures. Based on findings from these two months, it would be reasonable to believe that improper variances occurred in prior months as well. 另外，你们对FDA-483表的回复说，你公司已在2013年9月对已有程序进行了类似变更。你们的回复继续指出，在发现这些之后，你们审核了2013年8月的所有数据，又找到9个进行了额外测试但没有进行适当记录的事件。你们没有解释这是什么原因，对于这些发现的问题，你们没有将调查延伸以发现偏离已有程序的所有情况。基于对这2个月的调查发现，有理由相信在更早的时间段内也有类似情况发生。 The above examples demonstrate a general lack of reliability and accuracy of data generated by your firm's laboratory, which is a serious CGMP deficiency that raises concerns about the integrity of all data generated by your firm. We are concerned that your laboratory allowed the practice of retesting for GC, HPLC, and Karl Fischer methods without appropriate documentation, justification, and investigation. It is critical that you investigate these data integrity issues and identify the extent of these practices in your laboratory and manufacturing operations as part of a comprehensive data integrity audit. In your response, please also provide copies of the procedures in place that set forth the requirements to review and preserve complete data generated from your operations. 上述例子说明，你公司化验室所产生的数据普通缺乏可靠性和准确性，这是一个很严重的CGMP问题，使得我们对你公司所产生的所有数据的完整性均有担忧。我们担心你们化验室允许进行GC、HPLC和KF检测项目的复测，且没有适当的记录、判定和调查。你们很有必要对这些数据完整性问题进行调查，找出你们化验室里和生产操作中这些行为的所涉及的范围，作为数据完整性审计的一部分。在你们的回复中，请提供已有程序的复印件，设定审核的要求，保存你们公司操作中所产生的完整数据。 The failure to create and maintain accurate documentation is a repeat observation reported to your facility during the 2006 and 2010 inspections. 未能创建和维护准确的记录是2006年和2010年检查中发现的重复缺陷。 2. Failure to investigate and document out-of-specification results. 未能对OOS结果进行调查和记录 For example, 例如 · Your firm failed to investigate unknown peaks found during the HPLC testing for related compounds of API(b)(4) USP batch #(b)(4). A reviewer of the raw data reported on the “finished product report review data” worksheet that unknown peaks were observed due to vial contamination. The electronic records indicate that the first analysis performed on August 20, 2013, failed the specification ((b)(4)) limit for both any single unknown impurity ((b)(4)% vs. NMT (b)(4)%) and total impurities ((b)(4)% vs. NMT (b)(4)%). These OOS results were not reported or adequately investigated, and the raw data was discarded. The sample was re-analyzed on August 21, 2013, at which time it met specifications and the results were recorded. According to a laboratory analyst, the sample preparation printout corresponding to the initial testing (on August 20, 2013) was destroyed. · 你公司未能对原料药XXXUSP批号YYY有关物质HPLC检测中未知峰进行调查。对在“成品报告审核数据”工作表进行原始数据审核的人员报告说未知杂质原因是进样瓶被污染。电子记录显示在2013年8月20日进行了第一次分析，单个未知杂质X%和总杂均不符合标准规定。该OOS结果未进行报告或进行充分调查，原始数据被弃置。在2013年8月21日对样品重新进行了检测，这次样品符合标准规定，结果被记录下来。根据化验员所述，第一次（8月20日）样品制备打印记录已被销毁。 · Your firm’s investigation of the data from the Empower software identified instances where additional testing was performed but not properly documented in laboratory records. This investigation was limited in scope to only a short timeframe, the month of August 2013, and to only one type of laboratory instrumentation, HPLC. During FDA’s inspection, the QC manager explained that the scope of the risk assessment was limited to the month of August 2013 because he was busy with other laboratory responsibilities. According to your response to the Form FDA-483, some of the corrective actions implemented as a result of this investigation include: re-training of QC analysts, revision of the laboratory incident investigations SOP, and enhancements to the documentation and sample handling practices. As failures to investigate and document OOS results have persisted, it is clear that your corrective actions were not sufficient. · 你公司对EMPOWER工作站数据调查显示，你们做了一些额外检测但并没有在化验室记录本上进行适当的记录。该调查仅局限于一个较短的时间段，即2013年8月期间，局限于单一种检测仪器，即HPLC。在FDA检查中，QC经理解释说风险评估的范围局限于2013年8月这一个月是因为他忙于化验室的其它事务。根据你们对FDA483表格的回复，你们根据调查结果实施了一些纠正措施，包括：对QC化验员进行重新培训、修订化验室事故调查SOP、加强记录和样品处理操作管理。但对未调查和记录OOS结果的情况仍在持续，很显然你们的纠正措施并不充分。 · An email chain from December 26, 2013 to January 21, 2014, reviewed during the inspection, discussed an unexpected unknown peak observed in the residual solvents release test for (b)(4) batches (b)(4) and (b)(4). Your firm acknowledged during the inspection that SOP QC 098/01 “Laboratory Incident Investigation and Resolution” was not followed. During the inspection, a Quality Control manager stated that this incident was not investigated and resolved because this was an unknown peak and no failure had been identified. · 在检查中审核了从2013年12月26日至2014年1月21日一系列的电子邮件，其中讨论了在XX批和YY批放行检测残留溶剂项目中发现了意外的未知峰。在检查期间你们公司说你们没有按照SOP QC 098/01“化验室事件调查和处理程序”进行调查。在检查期间，一个QC经理说该事件未经过调查和处理，因为这是一个未知峰，不认为这是一个事件。 Your management failed to prevent the practices of product sample retesting without investigation, and rewriting and/or omission of original CGMP records persisted without implementation of controls to prevent data manipulation. 你们管理层未能防止未经调查即对产品样品进行复测，以及重新书写和/或忽略原始CGMP记录事件反复发生，未能实施控制以防止对数据篡改。 Your firm’s response to the Form FDA-483 acknowledges the deficiencies regarding data integrity observed during this inspection. Nevertheless, your firm’s health hazard evaluation “Drug Safety Analysis” conducted in response to the Form FDA-483 concluded that there was no effect on product quality or patient safety. However, this evaluation was based on unreliable and incomplete data, as undesired records appear to be excluded. For instance, your report failed to include all of the batches tested, and did not list all of the customers you notified other than Apotex, Inc. Your response to the previous 2010 inspectional findings stated that “We are confident that … SOPs covering OOS … and Deviation … will provide the necessary control over the system to ensure consistent application and on-going compliance to this requirement.” However, you clearly failed to detect and investigate the inaccurate data found by our investigators during this recent inspection. 你公司对FDA483表的回复中说明了关于本次检查中发现的数据完整性缺陷，你们公司在回复FDA483表时所做的卫生安全评估“药品安全性分析”做出结论说对产品质量或患者安全没有影响。但是，该评估是基于不可靠不完整的数据所得出的结论，不符合结论的记录显然未被包括在评估中。例如，你们的报告未能包括所有被检测的批次，未能列出除APOTEX公司以外的其它被通知的客户。你们在对2010检查缺陷的回复中声明“我们相信……SOP包括OOS……和偏差……能给系统进行必要的控制，以保证持续应用和符合该要求”，而在此次最近的检查中，显然你们未能发现并调查我们在检查中所发现的不准确数据。 In response to this letter, you should provide documentation of all corrective actions taken by your firm to address these failures to initiate investigations as required by your procedures and determine root cause(s) of OOS results. 在对本信的回复中，你们要提交你们公司所实施的纠正措施的所有记录，说明这些失效情况，根据你们的程序启动调查，确认OOS结果的根本原因。 The failure to perform adequate investigations is a repeat observation reported to your facility during the 2006 and 2010 inspections. 缺陷“未能进行充分调查”在2006年和2010年对你公司检查中重复出现。 3. Failure to include adequate documentation during complaint investigation. 在客诉调查中未能进行充分的文件记录。 Your firm received complaint #(b)(4) for (b)(4) USP batch #(b)(4) due to failing assay results. The original investigation, approved on March 29, 2013, indicated that the complaint was received on February 26, 2013. During the review of that investigation, our investigators found a test record from January 8, 2013 (prior to the date you documented receiving the complaint) that reported failing HPLC assay results of the retain sample of batch (b)(4). This record was not included in the investigation report. Your response to the Form FDA-483 observation included an addendum to the investigation report that indicated the complaint/query was actually received on January 8, 2013. 你公司收到USP批次XX的客诉，客诉是关于含量结果不符合要求的。原始调查在2013年3月29日被批准。调查显示2013年2月26日收到客诉。在对该客诉进行审核时，我们的检查人员发现2013年1月8日有一份检验记录（日期在你们记录所收到的客诉之前），其中报告XX批次留样的HPLC含量结果不符合规定。该记录没有放入调查报告中。你们对FDA483表的回复中包括了一份对调查报告的增补文件，说明客诉实际是在2013年1月8日收到的。 Your firm’s response acknowledges that the assay result for the retain sample was omitted, but also claims additional investigations are ongoing and that preventive and corrective actions will be implemented as appropriate. However, your response to the previous 2010 inspectional findings included a similar corrective action plan regarding OOS, deviations, stability, product complaint and CAPA investigations. In this plan, you committed “to address this omission and provide assurances that the scope and detail related to future investigations is appropriately documented … to ensure consistent consideration for failure investigations.” 你们公司的回复说留样的含量检测结果被忽略了，同时声明还在进行额外的调查，必要时将实施预防措施和纠正措施。但是，你们在对2010年检查缺陷的回复中，也有同样的关于OOS、偏差、稳定性、产品投诉和CAPA调查的纠正计划。在该计划中，你们承诺“会重视该种忽略，保证将来调查的范围和细节会被适当地记录……以保证失败情况下的调查会得到统一的考虑”。 In response to this letter, you should provide evidence of the additional investigation conducted and the corrective actions implemented to prevent the omission of data. Provide records of all complaints relating to your APIs, including returned API and the disposition of each returned batch. Discuss the expansion of your investigation to other batches and APIs that could be affected by failing assay results. Furthermore, explain the failure of your firm’s complaint system and how you will implement proper management oversight to ensure adequate corrections to this deficiency. 在对本信的回复中，你们要提交所进行的额外调查的证据，以及为防止对数据的忽略所实施的纠正措施的证据；提供所有与你们原料药客户投诉有关，包括与退货原料药和对每个退回批次处理有关的记录。讨论将你们的调查扩大至可能受到不合格含量结果影响的其它批次和其它原料药。进一步对你公司客户投诉系统失效情况进行解释，以及说明你们如何实施适当管理监督以保证对该缺陷进行充分地纠正。 Your complaint investigation system was also identified as an observation during the 2010 inspection of your facility. 你们的客户投诉调查系统在2010年检查中同样是作为缺陷的。 4. Failure to record activities at the time they are performed. 未能在活动实施时及时进行记录。 Specifically, your staff used “finished product reports review data” worksheets to document critical laboratory information days after the actual testing was performed. The worksheets reported observations from your firm’s secondary reviewer, and next to each of these listed observations the analyst marked them as corrected. A review of these worksheets revealed that your analysts did not always record data in the laboratory records in a contemporaneous manner as noted in the following examples: 特别是，你们员工在实际检测完成若干天之后使用“成品报告审核数据”表来记录关键的化验室信息。该表中报告了你公司副审核员发现的问题，在每个列出的问题旁边，化验员将它们标记为修订。对这些工作表的审核揭示你们化验员有时未能同步将数据记录在化验室记录上，以下是一些例子： · (b)(4) USP batch #(b)(4) worksheet dated September 18, 2013, reports “sample wt. taken wrongly." However, the correction to the stability data sheet for this lot gives the appearance that sample weighing was performed on August 10, 2013. · 日期为2013年9月18日XXUSP批次YY工作表中，报告“样品重量称取错误”，但是，对该批次稳定性数据表的修改显示该样品是在2013年8月10日称重的。 · (b)(4) USP batch #(b)(4) worksheet dated September 19, 2013, reports “all tests completed but appearance not reported.” However, the correction to the test record indicates the test was performed on September 15, 2013, the date of the original testing. · 日期为2013年9月19日的XXUSP批次YY工作表中，报告“所有检测均完成，但外观没有报告”，但是，对该检测记录的修正显示外观检测是在2013年9月15日（初始检测日期）就做了。 · (b)(4)% batch #(b)(4) worksheet dated June 11, 2013, reports “resolution b/t (b)(4) & (b)(4) in ID std not in working std & it is (b)(4) not (b)(4).” However, the correction to the stability test data sheet for this lot gives the appearance that the resolution was performed on June 9, 2013. · 日期为2013年6月11日XXUSP批次YY工作表中，报告“鉴别对照中A和B的分离度不在工作对照标中，它是A不是B”，但是对该批稳定性试验数据表的修正显示分离度在2013年6月9日就做了。 Your firm’s procedure SOP QA008/02 “Documentation Practices” prohibits backdating or re-creating document entries without supporting documents, and instructs your staff that the data must be recorded on the CGMP document at the time the activity is performed. Your response indicates that you revised SOP QA008/02 "Documentation Practices" to clarify how to document missed entries with appropriate retraining. While we acknowledge your commitments for retraining on the revised procedure, we remain concerned about the capability and credibility of your quality control laboratory. Our inspection revealed that your firm selectively omitted CGMP records directly related to the testing and manufacturing of your products. You are responsible for the accuracy and integrity of the data generated by your firm. A firm must maintain all raw data generated during each testing and manufacturing operation, including graphs, charts, and spectra from laboratory instrumentation. You must properly identify these records to demonstrate that each released batch was manufactured in accordance with validated parameters, was tested appropriately, and met release specifications. Your firm's executive management is responsible for ensuring the quality and safety of your products. Implementing adequate controls and systems to prevent omission and manipulation of laboratory data is at the foundation of fulfilling this critical responsibility. The above examples raise serious concerns regarding the integrity, reliability and accuracy of the data generated and available at your facility. In your response to this letter, provide a comprehensive evaluation of the extent of the omission, deletion and destruction of records, a risk assessment regarding the potential impact on the quality of products, and a comprehensive corrective and preventive action plan. Your response should include a summary of your investigation into missing, inaccurate or unreliable tests results with a description the findings. Your investigation should assess the impact of these and any similar incidents on the quality of the drug products produced with your APIs, and should describe the steps that will be taken to prevent these fundamental breaches of data integrity and management oversight in the future. Your plan should also ensure that controls are put in place that are sufficient to prevent omissions of data and prevent unauthorized changes to existing data. Any changes to data should only occur in strict accordance with approved established procedures, and the date of change, identity of person who made the change, and an explanation or reason for the change should always be recorded. Your firm also needs to improve its procedures for analyzing complaints, handling OOS results, and assuring effectiveness of corrections following investigations into deviations and OOS results. Accordingly, you should include a detailed description of your plan to implement a robust quality system in your response to this letter. This remediation plan should describe the broader steps taken to ensure direct and effective corporate oversight of the quality and operation functions of this facility. This system should ensure sustainable compliance with CGMP, including the basic capability to prevent data manipulation and destruction or deletion of records. Your plan should also describe your commitment, procedures, actions, and controls to ensure data integrity generally. This plan should describe the corrective actions implemented to ensure that all managers, supervisors, and quality unit personnel are properly trained in detecting a lack of data integrity and data manipulation. The investigation should provide detailed descriptions of any other incidents where your quality unit failed to ensure proper testing of any materials and should include a retrospective review of all test results generated by your laboratory personnel. 你们的计划还要说明你们的承诺、程序、行动及控制，以保证总体的数据完整性。该计划要描述所实施的纠正计划，以保证所有经理、主管和质量部门人员受到适当的培训，可以发现数据完整性和篡改数据问题。调查要提供对所有其它质量部门失败事件的详细描述，以保证对所有物料进行适当测试；要包括对所有由你们化验室人员得到的检测结果进行回顾性审核的报告。 Please note that the guidance document entitled "Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients" (ICH CGMP guidance), prepared under the auspices of the International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, describes current good manufacturing practice (CGMP) for the manufacture of APIs. The guidance is intended to help ensure that all APIs meet the standards for quality and purity they purport or are represented to possess. FDA considers the expectations outlined in ICH Q7, as well as alternatives intended to accomplish the same goals and provide an equivalent level of quality assurance, in determining whether a firm's APIs have been manufactured, processed, packed, and held according to current good manufacturing practice under section 50l(a)(2)(B) [21 USC 35l(a)(2)(B)] of the Act. To obtain the ICH CGMP guidance document for your reference, please refer to the following page of FDA's website: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryinformation/Guidances/UCM073497.pdf We acknowledge that you committed to hiring a third party auditor with experience in detecting data integrity problems to assist you with this evaluation and to assist with your overall compliance with CGMP. Your data integrity consultant should: 我们得知你们承诺要聘请第三方有经验的审计人员，找出数据完整性问题，协助你们进行评估，并在整个CGMP符合性方面协助你们。你们的数据完整性顾问应该： 1. Identify any historical period(s) during which inaccurate data reporting occurred at your facilities. 找出你公司不准确数据报告发生的历史时间段。 2. Identify and interview your current employees who were employed prior to, during, or immediately after the relevant period(s) to identify activities, systems, procedures, and management behaviors that may have resulted in or contributed to inaccurate data reporting. 找出在相关相关时间段之前、期间及之后加入公司的现有员工，与他们面谈，找出可能会导致或对不准确数据报告有责任的活动、系统、流程和管理行为。 3. Identify former employees who departed prior to, during, or after the relevant periods and make diligent efforts to interview them to determine whether they possess any relevant information regarding any inaccurate data reporting. 4. Determine whether other evidence supports the information gathered during the interviews, and determine whether additional facilities were involved in or affected by inaccurate data reporting. 5. Use organizational charts and SOPs to identify the specific managers in place when the inaccurate data reporting was occurring and determine the extent of top and middle management involvement in, or awareness of, data manipulation. 6. Determine whether any individual managers identified in item (5) above are still in a position to influence data integrity with respect to CGMP requirements or the submission of applications; and establish procedures to expand your internal review to any other facilities determined to be involved in, or affected by, the inaccurate data reporting. 7. As part of this comprehensive data integrity audit of your laboratory, your audit report also should include any discrepancies between data or information identified in approved applications (including Drug Master Files), and the actual results, methods, or testing conditions submitted to the Agency. Include an explanation of the impact of all discrepancies. Provide a corrective action operating plan describing the specific procedures, actions and controls that your firm will implement to ensure integrity of the data in each application currently submitted to the Agency and all future applications. This should not only cover methods validation, but any other testing (e.g., stability tests, release tests) or operations you have performed for customers that may have been used to support a drug application-related submission to the agency. Finally, in response to this letter, you should also provide a list of all the batches of APIs in distribution and those intended to be shipped to the U.S. market that relied upon missing, inaccurate, or unreliable test data. 最后，在回复此信是时，你们还要提供一份清单，列出所有依赖于缺失的、不准确的或不可信的检测数据的在售原料药批号，及欲销往美国市场的批号。 The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of the deviations identified above and for preventing their recurrence and the occurrence of other deviations. If, as a result of receiving this warning letter or for other reasons, you are considering a decision that could reduce the number of finished drug products or active pharmaceutical ingredients produced by your manufacturing facility, FDA requests that you contact CDER's Drug Shortages Program immediately, as you begin your internal discussions, at drugshortages@fda.hhs.gov so that we can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Program also allows you to meet any obligations you may have to report discontinuances in the manufacture of your drug under 21 U.S.C. 356C(a)(1), and allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products. In appropriate cases, you may be able to take corrective action without interrupting supply, or to shorten any interruption, thereby avoiding or limiting drug shortages.
Until all corrections have been completed and FDA has confirmed corrections of the deviations and your firm’s compliance with CGMP, FDA may withhold approval of any new applications or supplements listing your firm as an API manufacturer. In addition, your failure to correct these deviations may result in FDA continuing to refuse admission of articles manufactured at Apotex Pharmachem India Pvt. Ltd. located at Plot # 1A Bommasandra Ind. Area, 4th Phase, Jigani Link Road, Bangalore, India into the United States. The articles are subject to refusal of admission pursuant to section 801(a)(3) of the Act, 21 USC § 381(a)(3), in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the Act, 21 USC § 351(a)(2)(B).
Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct and prevent the recurrence of deviations, and provide copies of supporting documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the date by which you will have completed the corrections. In addition, if you no longer manufacture or distribute the APIs at issue, provide the date(s) and reason(s) you ceased production. Please identify your response with FEI # 3005466325. Please send your reply to: Maan Abduldayem Compliance Officer U.S. Food and Drug Administration Center for Drug Evaluation and Research Office of Manufacturing and Product Quality Division of International Drug Quality White Oak, Building 51 room 4212 10903 New Hampshire Ave. Silver Spring, MD 20993 Sincerely, /S/ Thomas Cosgrove, J.D. Acting Director Office of Manufacturing and Product Quality Office of Compliance Center for Drug Evaluation and Research
CC: Dr. P.M. Akbarali Managing Director Apotex Pharmachem India Pvt. Ltd. Plot # 1A Bommasandra Ind. Area 4th Phase, Jigani Link Road Bangalore, India – 560 099
| 
|手机版|蒲公英|ouryao|蒲公英
( 京ICP备14042168号-1 ) 增值电信业务经营许可证编号：京B2-20243455 互联网药品信息服务资格证书编号：(京)-非经营性-2024-0033
发表于 2014-6-29 20:40:52
置顶卡
变色卡
，谢谢。